An autoimmune disease is a condition in which your immune system mistakenly attacks your own healthy cells and tissues. Rather than targeting only bacteria, viruses, and other genuine threats, the immune system treats parts of your body as foreign invaders. These conditions affect roughly 8% to 10% of the world’s population, and their prevalence is rising.
How the Immune System Turns on Itself
Your immune system normally learns to tell the difference between your own cells and outside threats through a process called tolerance. This education happens in two stages. The first occurs before birth and during early development, when immune cells are exposed to your body’s own molecules. Cells that react too strongly to your own tissue are destroyed. Cells that respond appropriately to foreign material are kept.
This first stage isn’t perfect. Some self-reactive immune cells slip through, so your body relies on a second layer of safety checks that operates throughout your life. These backup mechanisms keep those rogue cells inactive through several strategies: ignoring certain molecules, rendering self-reactive cells unresponsive, and using specialized regulatory cells to suppress them.
Autoimmune disease develops when both layers fail. The initial screening misses too many self-reactive cells, and the lifelong backup controls can’t contain them. Once activated, these cells produce autoantibodies, proteins that target your own tissues instead of invaders. The result is chronic inflammation and tissue damage in whatever organ or system the immune attack is directed at.
Why Women Are Disproportionately Affected
Four out of every five people diagnosed with an autoimmune disease are female. Researchers at Stanford University identified one likely reason: a molecule called Xist that exists only in female cells. Every cell in a woman’s body has two X chromosomes, but only one is needed. To prevent a double dose of X chromosome genes, each cell shuts down one copy using Xist and a complex of more than 80 associated proteins.
The problem is that the immune system sometimes recognizes those associated proteins as foreign. Autoantibodies targeting dozens of proteins in this complex were found in people with autoimmune diseases but not in healthy individuals. The Xist complex doesn’t cause autoimmune disease on its own, but it appears to help trigger it in people who are already vulnerable due to genetics or environmental exposures.
Genetics and Environmental Triggers
Genetics account for roughly 30% of autoimmune disease risk. The most important genetic factor is a cluster of genes called the Human Leukocyte Antigen (HLA) complex, which helps your immune system distinguish self from non-self. Certain variations in these genes make the immune system more prone to misidentifying your own tissue as a threat.
The remaining 70% of risk comes from environmental factors. These include infections, toxic chemical exposures, dietary components, and imbalances in gut bacteria. Specific triggers that researchers have linked to autoimmune disease onset include:
- Viral infections: Certain viruses can activate autoimmunity through molecular mimicry, where a viral protein closely resembles one of your own proteins, confusing the immune system into attacking both.
- Industrial chemicals: Trichloroethylene (a common industrial solvent), mercury, and asbestos have all been associated with increased autoimmune activity.
- BPA: This chemical, found widely in consumer products, is detectable in the urine of more than 90% of Americans and may contribute to immune disruption.
The Role of Gut Health
Your gut lining acts as a selective barrier, absorbing nutrients while keeping bacteria and their byproducts contained. Trillions of gut bacteria interact directly with your immune system, influencing how immune cells develop, which inflammatory signals they produce, and how tightly sealed the gut wall remains.
When the balance of gut bacteria is disrupted, the gut wall can become more permeable. Bacterial byproducts then leak into the bloodstream, triggering widespread immune activation and inflammation. This “leaky gut” phenomenon has been documented in several autoimmune conditions. In type 1 diabetes, for example, increased intestinal permeability often appears alongside or even before the autoimmune attack on insulin-producing cells. Bacteria that produce butyrate, a compound that helps maintain the gut barrier, tend to be depleted in people with autoimmune diseases, further weakening the barrier and creating a cycle of inflammation.
Common Autoimmune Diseases
There are more than 80 recognized autoimmune diseases. They differ based on which tissues the immune system targets, but they share the same underlying mechanism of misdirected immune activity. The most common include autoimmune thyroid disease (Hashimoto’s and Graves’ disease), rheumatoid arthritis, type 1 diabetes, psoriasis, multiple sclerosis, celiac disease, inflammatory bowel disease (Crohn’s and ulcerative colitis), lupus, and Sjögren’s syndrome.
Thyroid autoantibodies alone are present in 18% of U.S. adults, rising to 25% in older adults. Among people aged 60 and older, nearly one in three has at least one type of autoantibody associated with rheumatoid arthritis, thyroid disease, or celiac disease.
Prevalence Is Climbing
Autoimmune diseases are becoming significantly more common, and the increase is too fast to be explained by genetics alone. One key marker, antinuclear antibodies (a sign of immune system activity against the body’s own cells), was found in 22.3 million Americans in the late 1980s. By 2011 to 2012, that number had nearly doubled to 41.5 million. The sharpest increase was among adolescents, whose rates nearly tripled over the same period.
Globally, estimates suggest autoimmune disease incidence is increasing by about 19% per year. Type 1 diabetes has seen a consistent 3% to 4% annual increase in incidence over the past three decades. Researchers point to changing environmental exposures, shifts in diet, increased chemical pollution, and altered gut bacteria as likely contributors to the trend.
Symptoms and the Flare-Remission Cycle
The hallmark symptoms of autoimmune disease are redness, swelling, heat, and pain, all signs of inflammation. Beyond that, fatigue and muscle aches are extremely common across nearly all autoimmune conditions. Specific symptoms depend on which organ is under attack: joint stiffness in rheumatoid arthritis, skin plaques in psoriasis, numbness or vision changes in multiple sclerosis, digestive problems in celiac disease.
Most autoimmune diseases follow a pattern of flares and remissions. During a flare, symptoms intensify, sometimes severely. This can last days, weeks, or months. Eventually symptoms improve or disappear during remission, though the underlying condition remains. Flares can be unpredictable, but common triggers include stress, infections, sleep deprivation, and hormonal changes. Learning your personal triggers is one of the most useful things you can do to manage the condition over time.
How Autoimmune Diseases Are Diagnosed
Diagnosis typically begins with blood tests that look for autoantibodies. The most common screening test checks for antinuclear antibodies (ANA), which are present in many autoimmune conditions. A positive ANA result doesn’t confirm a specific disease on its own, but combined with symptoms, it points clinicians toward the right diagnosis. A negative ANA result generally rules out active connective tissue diseases like lupus.
If ANA is positive, the pattern and concentration of the antibodies help narrow things down. Different patterns correspond to different conditions. For instance, a speckled pattern is associated with lupus, Sjögren’s syndrome, and mixed connective tissue disease, while a centromere pattern points toward a limited form of scleroderma. Additional blood tests for specific antibodies, along with imaging and clinical evaluation, confirm the diagnosis.
Treatment Approaches
Treatment for autoimmune disease focuses on calming the overactive immune response and reducing inflammation. The approach depends on which disease you have and how severe it is.
For many conditions, the first line of treatment involves medications that broadly suppress immune activity. These reduce symptoms and slow tissue damage but can also lower your resistance to infections. Over the past two decades, biologic therapies have offered a more targeted approach. These drugs block specific inflammatory molecules, such as the signaling proteins that drive joint destruction in rheumatoid arthritis or the immune messengers that fuel skin inflammation in psoriasis. Because they target narrow pathways rather than the whole immune system, they tend to cause fewer broad side effects.
A newer class of oral medications works by blocking enzymes inside immune cells that relay inflammatory signals. These drugs can interrupt multiple inflammatory pathways at once, giving doctors a way to treat conditions that don’t respond to biologics. They’re taken as pills rather than injections, which many people prefer.
For severe, treatment-resistant cases, a form of cell therapy originally developed for blood cancers is showing remarkable early results. In small clinical trials, patients with refractory lupus who received this therapy saw their disease activity scores drop dramatically, with some achieving complete remission within months. Antibodies that had been attacking their own tissue became undetectable. Early trials in multiple sclerosis, myasthenia gravis, scleroderma, and rheumatoid arthritis have shown similar promise, though these studies remain small and long-term data is still being collected.